Advanced Prostate Cancer VL

Immune System Biology of Androgen and AR Functions in T cells in Prostate Cancer - Amy Moran

Details
Amy Moran joins Alicia Morgans in a discussion on the mechanisms of immunotherapy resistance in prostate cancer patients, and how androgens or the androgen receptor (AR) contribute. Amy Moran received a Prostate Cancer Foundation Young Investigator Award for this research which aims to reveal how androgens and AR activity regulate human T cell function and immunotherapy resistance and may reveal n...

Engineered Cell Therapies for Metastatic Castrate-Resistant Prostate Cancer - Saul Priceman

Details
At the 29th Annual Prostate Cancer Foundation (PCF) Scientific Retreat Dr Saul Priceman joins Alicia Morgans in a discussion on clinic-ready CAR T cell therapies for Metastatic castrate-resistant prostate cancer (mCRPC) that can overcome the limitations of prior CAR T cell products for prostate cancer. Dr. Priceman highlights the role of PCF's funds in impacting these research efforts. The project...

The Effect of Metastasis-Directed Therapy (MDT) on Oligometastatic Castration-Sensitive Prostate Cancer Outcomes - Philip Sutera

Details
In a conversation with Alicia Morgans, Phillip Sutera discusses his work in metastasis-directed therapy (MDT). Dr. Sutera gives a brief overview of the background of the research discussing the association between prostate-specific membrane antigen (PSMA) response and radiographic-progression-free survival among patients treated with stereotactic ablative radiation therapy in oligometastatic castr...

Geographic Variation in the Use of Doublet Therapy for Metastatic Prostate Cancer - Sam Washington

Details
Samuel Washington joins Alicia Morgans in a conversation on a population-based analysis evaluating geographic variations in the utilization of doublet therapy for metastatic prostate cancer patients. There is strong level-one evidence to support the use of combination therapies, in the form of doublet and triplet therapies in men with metastatic prostate cancer with overall survival benefits demon...

Using Liquid Biopsies in Clinical Practice to Inform Decision Making for Prostate Cancer Care - Joshua Lang

Details
Josh Lang joins Alicia Morgans in a discussion on the importance of understanding mechanisms of resistance to targeted therapies through the development of novel liquid biopsies of the human tumor microenvironment. Lang highlights his research which looks beyond tissue biopsy to liquid biopsies of cancer cells from a blood draw to inform decision-making. Research funded by the Prostate Cancer Foun...

Insights from the STAMPEDE Trial Platform - Marina Parry & Gerhardt Attard

Details
Marina Parry and Gerhardt Attard join Alicia Morgans in discussing two key studies from the STAMPEDE trial platform, including “Comparison of abiraterone acetate and prednisolone or combination enzalutamide + abiraterone acetate and prednisolone for metastatic hormone-sensitive prostate cancer (mHSPC) starting ADT: overall survival (OS) results of 2 randomized Phase III trials from the STAMPEDE pr...

CAR T and Cellular-Based Therapies - Vivek Narayan

Details
Vivek Narayan joins Alicia Morgans at ASCO 2022 to discuss his work with CAR T-cell therapies and prostate cancer, the first-in-human study. Using a low-dose escalation approach, Dr. Narayan and his team designed the study safety as the primary objective to evaluate the feasibility of manufacturing and delivering the CAR T-cells. He describes how findings showed both on-treatment toxicity and on-t...

Multidisciplinary Care for Patients, a Book Interview - Alicia Morgans

Details
Alicia Morgans sits down with Charles Ryan to discuss the recent publication of Urologic Oncology: Multidisciplinary Care for Patients, a book she co-edited with Kelly Stratton. Dr. Morgans shares her thoughts on the importance of collaboration across teams in treating patients with GU cancers and provides an overview of key content in the book. Biographies: Alicia Morgans, MD, MPH , Genitourinary...

Biomarker-Directed Therapy in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Clara Hwang

Details
Clara Hwang shares an overview of her ASCO 2022 poster session presentation with Alicia Morgans. Dr. Hwang explains how the research was motivated by the known disparities in Black versus white men regarding prostate cancer diagnosis and prognosis. She then describes how this study explored these disparities within the prostate cancer precision medicine space. Biographies: Clara Hwang, MD, Medical...

The Future of Radiopharmaceuticals in the Treatment of Prostate Cancer - Philip Kantoff

Details
Phil Kantoff, CEO of Convergent Therapeutics, sits down with Alicia Morgans to discuss the future of radioligand therapy in the treatment of advanced prostate cancer. Philip Kantoff provides an overview of exciting results seen in studies on actinium-225, a powerful alpha-emitter tested in patients with advanced prostate cancer that also may be promising for patients with earlier-stage disease. Bi...
email news signup